Toutes les études
RecrutementConfirmatoire thérapeutique (Phase III)Interventionnel

A phase 3b, prospective, open-label, multicenter, single treatment arm, continuation study of the safety and efficacy of TAK-755 (rADAMTS-13, also know as BAX930/SHP655) in the prophylactic and on-demand treatment of subjects with severe congenital thrombotic thrombocytopenic purpura (cTTP; Upshaw-Schulman Syndrome, or hereditary thrombotic thrombocytopenic purpura)

This study is a long-term look at a medicine called TAK-755, also known as rADAMTS-13. It's for people who have a rare, inherited blood clotting disorder called congenital thrombotic thrombocytopenic purpura (cTTP). The main goal is to understand the long-term safety of TAK-755. Researchers also want to see how well it works to prevent TTP episodes in people who take it regularly, as a preventative measure. They will compare new patients to those who have already been in an earlier study. This is a Phase 3 study, meaning it's a key step in testing new treatments to see if they should be approved for wider use.

En un coup d'œil

Statut
Recrutement
Phase
Confirmatoire thérapeutique (Phase III)
Sponsor
Baxalta Innovations GmbH
Objectif d'inscription
30
Démarrer
18 Jul 2024

De quoi parle cette étude ?

This study is looking into a medicine called TAK-755 for people with a rare, inherited blood condition called congenital thrombotic thrombocytopenic purpura, or cTTP for short. Because it's passed down through families, it's sometimes called hereditary TTP. People with cTTP have problems with their blood clotting system, which can lead to serious health issues. TAK-755 is designed to help correct this problem.

The main focus of this study is to see how safe TAK-755 is over a longer period. While previous studies might have looked at its immediate effects, this one wants to gather more information about its safety when used for an extended time. Besides safety, the researchers are also very interested in how well TAK-755 can prevent sudden, serious attacks of TTP when people take it regularly, as a preventative treatment.

This is an ongoing study, which means it builds on previous research. It's a 'Phase 3' study, which is an important stage where new medicines are tested in a larger group of people to confirm their safety and how well they work before they can be considered for wider use. By gathering more information, this study aims to help doctors understand if TAK-755 could be a good long-term treatment option for people with cTTP.

Points clés

  • Targets inherited blood clotting disorder (cTTP).
  • Focuses on long-term safety of TAK-755.
  • Also assesses how well TAK-755 prevents TTP episodes.
  • Open to adults aged 18 and older.
  • Is a continuation study; some participants may have been in previous trials.

Qui peut être éligible ?

To be able to join this study, participants need to be at least 18 years old, and there is no upper age limit. The study is open to both men and women.

The main requirement is that you must have a diagnosis of severe congenital thrombotic thrombocytopenic purpura (cTTP), also known as Upshaw-Schulman Syndrome or hereditary thrombotic thrombocytopenic purpura. This means your condition is inherited and can be quite serious.

Some participants might be new to TAK-755, while others may have already taken part in a previous study involving this medicine. The study will look at both groups to get a full picture.

Cet étude pourrait-elle vous convenir ?

Répondez à ces questions rapides pour voir si vous êtes éligible. Ceci est un guide uniquement — l'équipe de recherche prend la décision finale.

  1. Avez-vous 18 ans ou plus ?
  2. Do you have a diagnosis of severe congenital thrombotic thrombocytopenic purpura (cTTP) (also known as Upshaw-Schulman Syndrome or hereditary TTP)?
  3. Are you able to attend regular clinic visits and follow study instructions?
  4. Have you discussed your interest in this study with your doctor?
Répondez à chaque question pour voir votre résultat.

En quoi consiste la participation ?

If you decide to take part in this study, you'll be given the study medicine, TAK-755. You'll take it either regularly to prevent TTP episodes (prophylactic treatment) or when you have symptoms of an episode (on-demand treatment), as decided by the study doctors.

Throughout the study, you'll have regular visits to the clinic. At these visits, doctors and nurses will carry out various tests and checks to monitor your health, how the medicine is affecting you, and if you've had any TTP events. This will include blood tests and physical examinations. The total duration of your participation will depend on the study's design, as it's a continuation study following up on previous research.

Risques et avantages potentiels

Participating in this study might offer you access to a new treatment for cTTP under close medical supervision, which could potentially help manage your condition and prevent TTP episodes. However, as with any medicine, there is a possibility of side effects or risks when taking TAK-755, and the study aims to understand these better over the long term. You will be closely monitored for any reactions. It's important to remember that you are free to withdraw from the study at any time, for any reason, without it affecting your usual medical care.

Emplacements (6)

Certains emplacements de site sont approximatifs. Nous améliorons cela — veuillez vérifier avec l'équipe d'essai avant de vous déplacer.
  • —
    Non vérifié
    France
  • —
    Non vérifié
    Allemagne
  • —
    Non vérifié
    Autriche
  • —
    Non vérifié
    Italie
  • —
    Non vérifié
    Espagne
  • —
    Non vérifié
    Pologne

Questions fréquentes

What is congenital TTP?

Congenital TTP is a rare, inherited blood disorder that can cause serious problems with blood clotting and lead to low platelet counts and red blood cell damage.

What is TAK-755?

TAK-755 is a medicine that aims to help people with congenital TTP by replacing a missing protein that helps control blood clotting.

Pourquoi cette étude est-elle menée ?

This study is primarily to learn more about the long-term safety of TAK-755 and how well it prevents TTP episodes in people with congenital TTP.

Who can take part in this study?

Adults aged 18 or over, with a diagnosis of severe congenital TTP, can potentially join this study.

Devrai-je payer pour participer à l'étude ?

No, you will not have to pay for the study medicine or the medical tests directly related to the study.

Comment en savoir plus

Parlez toujours à votre médecin généraliste ou spécialiste avant de décider de participer à une étude.

Intéressé à participer ?

Inscrivez votre intérêt

Partagez vos coordonnées et l'équipe de recherche pour "A phase 3b, prospective, open-label, multicenter, single tre… vous contactera si vous êtes éligible. Consultez toujours votre médecin avant d'accepter de participer.

Discussion

Discussion communautaire

Propulsé par notre forum à community.patient.info. Veuillez être respectueux — ceci n'est pas un avis médical.